Harbin Biotech Advances BsADC Overseas Development; Sino Biopharmaceutical Announces Two Major Licensing Deals on Same Day

Jul 08, 2026 18:36 CST Updated 18:36

Sino Biopharm

Pharmaceutical R&D Developer

AstraZeneca

Pharmaceutical Technology Research and Development Provider

GSK China

Pharmaceutical Manufacturer

GSK

Pharmaceutical R&D Manufacturer

CHIATAI TIANQING

High-quality pharmaceuticals research, production, and sales provider

Biocytogen

Antibody Drug Developer

Sino Biopharm Partners with AstraZeneca

7Month8Day, Sino Biopharm（hereinafter referred to as“Sino Biopharm”）Issued an announcement regarding the independently developed chronic obstructive pulmonary disease (COPD) Innovative DrugsTQC3721（PDE3/4inhibitor) overseas rights for a total amount up to the highest19$100 million licensed to AstraZeneca.

The announcement stated that Sino Biopharm will grant AstraZeneca the rights to develop, manufacture, and commercialize [the product] in regions outside China. TQC3721exclusive license. AstraZeneca will also obtainTQC3721Global Specific Development Plan （Including China） Exclusive License. Sino Biopharm is entitled to obtain2hundred million USD in upfront payment, and up to17$ billion in potential development, regulatory, and sales milestone payments, as well as tiered royalties.

Clinical data show that, compared withEnsifentrine，TQC3721Additionally include those with more severe disease conditionsCOPDPatients, broader coverageCOPDPatient Population, inFEV1(The volume of air exhaled in the first second of maximal expiration, for diagnosing asthma andCOPDcommonly used indicators) improvement andSGRQScore (a method used to evaluateCOPDstandardized questionnaires for quality of life in patients with other respiratory diseases) and demonstrated superior data across multiple dimensions, including improvement.

Notably,TQC3721authorized transaction, also marking Sino Biopharm's second such deal this year2Month and Sanofi Reach Agreement on Rofacitinib15.3the second out-licensing deal with a multinational pharmaceutical company this year, following the hundred-million-dollar authorization partnership. Two consecutive major outboundAuthorized Transaction, indicating that the company has entered a normalized phase of out-licensing, which is expected to deliver certain and stable profit growth.

CHIATAI TIANQING and GSK Make Another Strategic Move in Their Partnership

7Month8Sino Biopharm Announces Further Expansion of Partnership with GSK（GSK）strategic cooperation, conducted through the core enterprise CHIATAI TIANQING for Trelegy (fluticasone fumeate/umeclidinium/vilanterol inhalation powder),FF/UMEC/VI) and Anoro Ellipta (umeclidinium bromide and vilanterol inhalation powder,UMEC/VI) commercial operations in mainland China.

This collaboration is based on both parties'2026Year5Announced in JuneBeiparvovirsenA key initiative to expand the strategic partnership footprint from liver diseases further into the field of chronic respiratory diseases. CHIATAI TIANQING is a leading enterprise in the field of respiratory diseases, and this collaboration will cover more than 9000hospitals and primary healthcare institutions, further enhancing the accessibility of the two drugs to enable more patients to benefit as soon as possible.

Under the expanded cooperation agreement, CHIATAI TIANQING will be responsible for carrying out the import, distribution, hospital access, and promotional and non-promotional activities of Trelegy Ellipta and Anoro Ellipta in mainland China. GlaxoSmithKline PLC. will continue to serve as the marketing authorization holder for the two drugs (MAH), responsible for overseeing regulatory affairs, quality control, pharmacovigilance, and global brand strategy.

Biocytogen Advances Overseas Development of Bispecific Antibody ADCs

7Month7On [date], Biocytogen andWhitehawk TherapeuticsAnnounced the signing of a global strategic cooperation agreement, focusing on multiple bispecific antibody-drug conjugates (BsADC) joint development of the project. Biocytogen providesRenLiteFull-human bispecific antibody discovery platform,WhitehawkProvideCPT113Connexin－Load andCBCRConjugation Technology, Jointly Advancing the Next GenerationADCPipeline.

Biocytogen throughRenLiteThe platform provides up to5Fully human bispecific antibody,WhitehawkCombined with proprietaryADCThe platform evaluates these antibodies, and subsequently selects the generatedBsADCThe candidate asset has been incorporated into the pipeline for further development. Financially, Biocytogen received an upfront payment and is entitled to R&D, regulatory, and commercialization milestone payments, as well as low single-digit royalties on product sales. Specific amounts were not disclosed. IfWhitehawkExercise the option to holdBsADCglobal rights and full project leadership. The complementarity between the two companies is the core of this transaction.

It is worth noting that the financial details of this transaction were not disclosed. Biocytogen2024Year andIdeayaandSotiotransactions are clearlybiobucksTotal Amount: Confidential for this selection. According toWhitehawk...theory, in the future12-24There will be newADCProject SubmissionIND, provided by Biocytogen5This bispecific antibody molecule will gradually enter the evaluation phase. Whether this timeline can be realized requires continuous monitoring.